Telomerase inhibition with an oligonucleotide telomerase template antagonist: In vitro and in vivo studies in multiple myeloma and lymphoma

Blood

Volumn 103, Issue 1, 2004, Pages 258-266

  Wang, Eunice S ^b   Wu, Kaida ^b   Chin, Allison C ^b   Chen Kiang, Selina ^b   Pongracz, Krisztina ^b   Gryaznov, Sergei ^b   Moore, Malcolm A S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

OLIGONUCLEOTIDE; PHOSPHOROTHIOIC ACID DERIVATIVE;

ARTICLE; B LYMPHOCYTE ACTIVATION; CELL DEATH; CELL IMMORTALIZATION; CONTINUOUS INFUSION; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC COMPLEMENTATION; HUMAN; HUMAN CELL; LYMPHOMA; MULTIPLE MYELOMA; OLIGONUCLEOTIDE PROBE; ONCOGENE N RAS; PRIORITY JOURNAL; RECEPTOR UPREGULATION; TELOMERE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 0346336773     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-02-0546     Document Type: Article

References (51)

1. Shay JW, Zou Y, Hiyama E, Wright WE. Telomerase and cancer. Hum Mol Genet. 2001;10:677-685.
2. Collins K, Mitchell JR. Telomerase in the human organism. Oncogene. 2002;21:564-579.
3. Harley CB. Telomerase is not an oncogene. Oncogene. 2002;21:494-502.
4. Hahn WC, Stewart SA, Brooks MW, et al. Inhibition of telomerase limits the growth of human cancer cells. Nat Med. 1999;5:1164-1170.
5. Boklan J, Nanjangud G, MacKenzie KL, May C, Sadelain M, Moore MA. Limited proliferation and telomere dysfunction following telomerase inhibition in immortal murine fibroblasts. Cancer Res. 2002;62:2104-2114.
6. Seimiya H, Oh-hara T, Suzuki T, et al. Telomere shortening and growth inhibition of human cancer cells by novel synthetic telomerase inhibitors MST-312, MST-295, and MST-1991. Mol Cancer Ther. 2002;1:657-665.
7. Damm K, Hemmann U, Garin-Chesa P, et al. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J. 2001;20:6958-6968.
8. Izbicka E, Wheelhouse RT, Raymond E, et al. Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells. Cancer Res. 1999;59:639-644.
9. Grand CL, Han H, Munoz RM, et al. The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Mol Cancer Ther. 2002;1:565-573.
10. Pang JX, Cheng XY, Xu W, Wu SG. Antisense Spl oligodeoxynucleotide decreases telomerase activity by inhibiting hTERT mRNA expression in Jurkat T cells. Acta Pharmacol Sin. 2003;24:91-96.
11. Herbert B, Pitts AE, Baker SI, et al. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc Natl Acad Sci U S A. 1999;96:14276-14281.
12. Herbert BS, Pongracz K, Shay JW, Gryaznov SM, Shea-Herbert B. Oligonucleotide N3′→P5′ phosphoramidates as efficient telomerase inhibitors. Oncogene. 2002;21:638-642.
13. Weng NP, Regulation of telomerase expression in human lymphocytes. Springer Semin Immunopathol. 2002;24:23-33.
14. Ohyashiki JH, Sashida G, TauchiT, Ohyashiki K. Telomeres and telomerase in hematologic neoplasia. Oncogene, 2002;21:680-687.
15. Nilsson P, Mehle C, Remes K, Roos G. Telomerase activity in vivo in human malignant hematopoietic cells. Oncogene. 1994;9:3043-3048.
16. Weng NP, Granger L, Hodes RJ. Telomere lengthening and telomerase activation during human B cell differentiation. Proc Natl Acad Sci U S A. 1997;94:10827-10832.
17. Norrback KF, Dahlenborg K, Carlsson R, Roos G. Telomerase activation in normal B lymphocytes and non-Hodgkin's lymphomas. Blood. 1996;88:222-229.
18. Xu D, Zheng C, Bergenbrant S, et al. Telomerase activity in plasma cell dyscrasias. Br J Cancer. 2001;84:621-625.
19. Shiratsuchi M, Muta K, Abe Y, et al. Clinical significance of telomerase activity in multiple myeloma. Cancer. 2002;94:2232-2238.
20. MacNamara B, Wang W, Chen Z, et al. Telomerase activity in relation to pro- and anti-apoptotic protein expression in high grade non-Hodgkin's lymphomas. Haematologica. 2001;86:386-393.
21. Remes K, Norrback KF, Rosenquist R, Mehle C, Lindh J, Roos G. Telomere length and telomerase activity in malignant lymphomas at diagnosis and relapse. Br J Cancer. 2000;82:601-607.
22. Ely SA, Chadburn A, Dayton CM, Cesarman E, Knowles DM. Telomerase activity in B-cell non-Hodgkin lymphoma. Cancer. 2000;89:445-452.
23. Bechter OE, Eisterer W, Pall G, Hilbe W, Kuhr T, Thaler J. Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia. Cancer Res. 1998;58:4918-4922.
24. Wu K, Orme L, Shaughnessy JJ, Jacobson J, Barlogie B, Moore MAS. Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival. Blood. 2003;101:4982-4989.
25. Akiyama M, Hideshima T, Hayashi T, et al. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res. 2002;62:3876-3882.
26. Akiyama M, Hideshima T, Hayashi T, et al. Nuclear factor-κB p65 mediated tumor necrosis factor alpha nuclear translocation of telomerase reverse transcriptase protein. Cancer Res. 2003;63:18-21.
27. Blackburn EH. Switching and signaling at the telomere. Cell. 2001;106:661-673.
28. Ouellette MM, Liao M, Herbert BS, et al. Subsenescent telomere lengths in fibroblasts immortalized by limiting amounts of telomerase. J Biol Chem. 2000;275:10072-10076.
29. Steinert S, Shay JW, Wright WE. Transient expression of human telomerase extends the life span of normal human fibroblasts. Biochem Biophys Res Commun. 2000;273:1095-1098.
30. Gryaznov S, Pongracz K, Matray T, et al. Telomerase inhibitors-oligonucleotide phosphoramidates as potential therapeutic agents. Nucleosides Nucleotides Nucleic Acids. 2001;20:401-410.
31. Beckwith M, Longo DL, O'Connell CD, Moratz CM, Urba WJ. Phorbol ester-induced, cell-cyclespecific, growth inhibition of human B-lymphoma cell lines. J Natl Cancer Inst. 1990;82:501-509.
32. Ohsugi Y, Gershwin ME, Owens RB, Nelson-Rees WA. Tumorigenicity of human malignant lymphoblasts: comparative study with unmanipulated nude mice, antilymphocyte serum-treated nude mice, and X-irradiated nude mice. J Natl Cancer Inst. 1980;65:715-718.
33. Goy A, Gilles F, Remache Y, et al. Establishment of a human cell line (SKI-DLCL-1) with a t(1;14) (q21;q32) translocation from the ascites of a patient with diffuse large cell lymphoma. Leuk Lymphoma. 2001;40:419-423.
34. Gilles F, Goy A, Remache Y, Shue P, Zelenetz AD. MUC1 dysregulation as the consequence of a t(1;14)(q21;q32) translocation in an extranodal lymphoma. Blood. 2000;95:2930-2936.
35. Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002;99:1745-1757.
36. Hardin J, MacLeod S, Grigorieva I, et al. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood. 1994;84:3063-3070.
37. Wu K, Higashi N, Hansen ER, Lund M, Bang K, Thestrup-Pedersen K. Telomerase activity is increased and telomere length shortened in T cells from blood of patients with atopic dermatitis and psoriasis. J Immunol. 2000;165:4742-4747.
38. Pruzan R, Pongracz K, Gietzen K, Wallweber G, Gryaznov S. Allosteric inhibitors of telomerase: oligonucleotide N3′→P5′ phosphoramidates. Nucleic Acids Res. 2002;30:559-568.
39. Mohammad RM, Wall NR, Dutcher JA, Al-Katib AM. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Clin Cancer Res. 2000;6:4950-4956.
40. Ludwig A, Saretzki G, Holm PS, et al. Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topolsomerase. Cancer Res. 2001;61:3053-3061.
41. Neumann AA, Reddel RR. Telomere maintenance and cancer-look, no telomerase. Nat Rev Cancer. 2002;2:879-884.
42. Sprung CN, Bryan TM, Reddel RR, Murnane JP. Normal telomere maintenance in immortal ataxia telangiectasia cell lines. Mutat Res. 1997;379:177-184.
43. Henson JD, Neumann AA, Yeager TR, Reddel RR. Alternative lengthening of telomeres in mammalian cells. Oncogene. 2002;21:598-610.
44. Delhommeau F, Thierry A, Feneux D, et al. Telomere dysfunction and telomerase reactivation in human leukemia cell lines after telomerase inhibition by the expression of a dominantnegative hTERT mutant. Oncogene. 2002;21:8262-8271.
45. Hemann MT, Strong MA, Hao LY, Greider CW. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell. 2001;107:67-77.
46. Corey DR. Telomerase inhibition, oligonucleotides, and clinical trials. Oncogene. 2002;21:631-637.
47. Roelofs H, De Pauw ES, Zwinderman AH, et al. Homeostasis of telomere length rather than telomere shortening after allogeneic peripheral blood stem cell transplantation. Blood. 2003;101:358-362.
48. Mo Y, Gan Y, Song S, et al. Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach. Cancer Res. 2003;63:579-585.
49. Yuan Z, Mei HD. Inhibition of telomerase activity with hTERT antisense increases the effect of CDDP-induced apoptosis in myeloid leukemia. Hematol J. 2002;3:201-205.
50. Lee KH, Rudolph KL, Ju YJ, et al. Telomere dysfunction alters the chemotherapeutic profile of transformed cells. Proc Natl Acad Sci U S A. 2001;98:3381-3386.
51. Franco S, Segura I, Riese HH, Blasco MA. Decreased B16F10 melanoma growth and impaired vascularization in telomerase-deficient mice with critically short telomeres. Cancer Res. 2002;62:552-559.